Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Up 47.4% in January

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totaling 415,924 shares, an increase of 47.4% from the December 31st total of 282,105 shares. Based on an average daily trading volume, of 161,860 shares, the short-interest ratio is currently 2.6 days. Approximately 4.5% of the shares of the company are sold short. Approximately 4.5% of the shares of the company are sold short. Based on an average daily trading volume, of 161,860 shares, the short-interest ratio is currently 2.6 days.

Hedge Funds Weigh In On Vivos Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. XTX Topco Ltd purchased a new stake in shares of Vivos Therapeutics during the 2nd quarter valued at about $65,000. B. Riley Wealth Advisors Inc. bought a new stake in Vivos Therapeutics during the second quarter worth approximately $220,000. Finally, Connective Capital Management LLC bought a new stake in Vivos Therapeutics during the third quarter worth approximately $620,000. 26.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Ascendiant Capital Markets decreased their target price on shares of Vivos Therapeutics from $6.50 to $5.50 and set a “buy” rating on the stock in a research note on Wednesday, December 3rd. HC Wainwright initiated coverage on shares of Vivos Therapeutics in a research report on Monday, November 17th. They set a “buy” rating and a $7.00 price objective on the stock. Zacks Research raised shares of Vivos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, December 1st. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Vivos Therapeutics in a research note on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $4.92.

Vivos Therapeutics Price Performance

NASDAQ:VVOS opened at $1.62 on Friday. The business’s 50-day moving average is $2.05 and its 200 day moving average is $3.12. Vivos Therapeutics has a 12 month low of $1.56 and a 12 month high of $7.95. The company has a market capitalization of $15.29 million, a P/E ratio of -0.92 and a beta of 6.89. The company has a current ratio of 0.78, a quick ratio of 0.78 and a debt-to-equity ratio of 3.31.

Vivos Therapeutics (NASDAQ:VVOS) last released its quarterly earnings data on Wednesday, November 19th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04. The business had revenue of $6.78 million for the quarter, compared to the consensus estimate of $4.49 million. Vivos Therapeutics had a negative return on equity of 351.28% and a negative net margin of 98.77%. On average, equities research analysts forecast that Vivos Therapeutics will post -1.79 earnings per share for the current fiscal year.

About Vivos Therapeutics

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.